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Abstract
CST6 is a breast tumor suppressor gene that is expressed in normal breast epithelium, but is
epigenetically silenced as a consequence of promoter hypermethylation in metastatic breast cancer
cell lines. In the current study, we investigated the expression and methylation status of CST6 in
primary breast tumors and lymph node metastases. 25/45 (56%) primary tumors and 17/20 (85%)
lymph node metastases expressed significantly lower levels of cystatin M compared to normal breast
tissue. Bisulfite sequencing demonstrated CST6 promoter hypermethylation in 11/23 (48%)
neoplastic lesions analyzed, including 3/11 (27%) primary tumors and 8/12 (67%) lymph node
metastases. In most cases (12/23, 52%), the expression of cystatin M directly reflected CST6 promoter
methylation status. In remaining lesions (8/23, 35%) loss of cystatin M was not associated with
CST6 promoter hypermethylation, indicating that other mechanisms can account for loss of CST6
expression. These results show that methylation-dependent silencing of CST6 occurs in a subset of
primary breast cancers, but more frequently in metastatic lesions, possibly reflecting progression-
related genomic events. To examine this possibility, primary breast tumors and matched lymph node
metastases were analyzed. In 2/3 (67%) patients, primary tumors were positive for cystatin M and
negative for CST6 promoter methylation, and matched metastatic lesions lacked cystatin M
expression and CST6 was hypermethylated. This observation suggests that progression-related
epigenetic alterations in CST6 gene expression can accompany metastatic spread from a primary
tumor site. Overall, the results of the current investigation suggest that methylation-dependent
epigenetic silencing of CST6 represents an important mechanism for loss of CST6 during breast
tumorigenesis and/or progression to metastasis.
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Introduction
Breast cancer is a heterogeneous disease that results from the accumulation of a complex series
of genetic and epigenetic events driving divergent pathways that ultimately convey varying
phenotypic properties to individual neoplastic lesions. Most invasive breast cancers
(approximately 90%) are of the ductal or lobular histopathological type (Symmans, 2005).
Numerous molecular markers have been examined for their predictive value in breast cancer
prognostication, but histopathologic grade emerges as the most important indicator of long-
term patient outcome (Simpson et al., 2005; Symmans, 2005). However, histopathologic grade
generally correlates with the expression of genes associated with increased cell proliferation
(Ki-67, p53), growth (HER-2), and invasiveness (matrix metalloproteinases) (Mirza et al.,
2002; Reed et al., 2000). In contrast, low-grade breast tumors express genes associated with
low cellular proliferation (p27) and differentiation (ER and PR) (Lau et al., 2001; Symmans,
2005). It is now accepted that there are two major pathways of multi-step breast cancer
progression, (i) well-differentiated ductal carcinoma in situ (DCIS) progressing to grade I
invasive ductal carcinoma (IDC), and (ii) poorly differentiated DCIS progressing to grade III
IDC (Simpson et al., 2005). Changes in the molecular pattern of DCIS lesions may lead to the
ability to collapse the myoepithelium, escape the duct structure, and invade the surrounding
stroma (Ai et al., 2006; Symmans, 2005). These IDC lesions will proliferate and grow,
destroying surrounding stroma, and breast architecture. Continued disease progression can lead
to tumor dissemination via lymphatic or hematogenous routes giving rise to metastatic lesions
in distant organs (Muller et al., 2005). At present, the molecular mechanisms that control tumor
progression, stromal invasion, and distant metastasis are poorly understood. Nevertheless, the
role of specific genes that contribute to breast cancer tumor invasion and metastasis are
beginning to be investigated and characterized.
Cystatin M (CST6) functions as an endogenous inhibitor of lysosomal cysteine proteases (Ni
et al., 1997; Sotiropoulou et al., 1997), which are known to contribute to tumor cell invasion
by degrading extracellular matrix components (Buck et al., 1992; Maciewicz et al., 1990; Mai
et al., 2002). Cathepsin B and cathepsin L are two important cysteine proteases that have been
implicated in tumor cell invasion and metastasis (Kane and Gottesman, 1990; Roshy et al.,
2003; Slone et al., 1981). Cystatin M is involved in regulating the activity of cathepsin B and
cathepsin L, and imbalances between these proteases and cystatin M may lead to the metastatic
phenotype in tumor cells (Frosch et al., 1999; Kos et al., 2000; Lah and Kos, 1998). Cystatin
M expression has been reported to be diminished or lost in various forms of cancer including,
(i) basal and squamous cell carcinomas of the skin (Zeeuwen, 2004), (ii) squamous cell
carcinomas of the head/neck and lung (Zeeuwen et al., 2002), (iii) non-small cell lung cancer
(Zhong et al., 2006), (iv) metastatic oral cancer cell lines (Vigneswaran et al., 2006), (v)
malignant glioma (Kim et al., 2006), and (vi) breast cancer (Ai et al., 2006; Rivenbark et al.,
2006a; Schagdarsurengin et al., 2006; Shridhar et al., 2004; Song et al., 2006; Sotiropoulou et
al., 1997; Zhang et al., 2004). Cystatin M contains a large CpG island that flanks the
transcription start site and spans the proximal promoter and exon 1 regions. CpG islands
represent well-characterized sites for DNA methylation, impairing transcription activation
related to regional or specific methylation events (Deng et al., 2004; Douglas et al., 2004;
Prendergast and Ziff, 1991). In a previous microarray-based analysis of differential gene
expression in MCF-7 breast cancer cells, we identified CST6 as a methylation-sensitive gene,
and demonstrated an inverse relationship between CST6 mRNA expression and methylation
of the proximal promoter region of its CpG island (Rivenbark et al., 2006b). In a subsequent
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study, methylation analysis of CST6 in breast cancer cell lines revealed an inverse correlation
between CpG island hypermethylation and CST6 gene expression, and the extent of regional
methylation in the proximal promoter was strongly correlated with the lack of CST6 expression
(Rivenbark et al., 2006a). Consistent with these findings, several other studies have shown that
CST6 is epigenetically regulated by DNA methylation-dependent silencing in breast cancer
cell lines and primary invasive ductal carcinomas (Ai et al., 2006; Schagdarsurengin et al.,
2006).
The aim of this study was to investigate cystatin M protein expression and CST6 gene
methylation status in primary breast cancers and lymph node metastasis in order to determine
if aberrant DNA methylation represents an important mechanism for the loss of CST6 during
neoplastic transformation of breast epithelium and/or breast cancer progression.
Immunochemical analysis revealed 25/45 (56%) primary breast tumors and 17/20 (85%) lymph
node metastases express significantly lower levels of cystatin M protein compared to normal
breast tissue. Bisulfite sequencing demonstrated CST6 promoter hypermethylation in 3/11
(27%) primary breast tumors and 8/12 (67%) lymph node metastases analyzed. In most cases
(12/23, 52%), the extent of CST6 promoter methylation was associated with the expression of
cystatin M protein. In other neoplastic lesions, (8/23, 35%) loss of cystatin M expression in
the absence of CST6 promoter methylation indicates that other mechanisms can account for
silencing of CST6. These results show that methylation-dependent epigenetic silencing of
CST6 occurs in a subset of primary breast tumors, but more frequently in metastatic lesions,
possibly reflecting the role of cystatin M in breast cancer progression/invasion. To examine
the possibility that CST6 is silenced by methylation during tumor progression, matched primary
breast tumors and lymph node metastases were analyzed. In our limited analysis, the majority
(2/3, 67%) of cystatin M-positive primary tumors (lacking CST6 promoter methylation) give
rise to cystatin M-negative lymph node metastases with hypermethylation of the CST6
promoter. Combined, the observations of the current study suggests strongly that CST6
promoter hypermethylation and loss of cystatin M expression affects a subset of human breast
cancers and that methylation-dependent epigenetic silencing of CST6 can occur during breast
tumorigenesis (early) or progression (late), contributing to tumor metastasis.
Materials and Methods
Human Breast and Lymph Node Tissues
This study included 87 paraffin-embedded human tissues corresponding to primary breast
tumors (n=54), lymph nodes metastases (n=22), and normal breast tissues (n=11). Twenty-one
archival human tissues (primary breast tumors, lymph node metastases, and normal breast)
were obtained from the University of North Carolina Lineberger Comprehensive Cancer Center
and 6 archival primary breast tumors were acquired from the Louisiana State University Health
Sciences Center. A breast tumor microarray (Imgenex Corporation, Sorrento Valley, CA)
consisting of 60 tissue cores was also utilized. In total, this study included 46 primary breast
specimens diagnosed invasive ductal carcinoma (IDC), 2 breast ductal carcinoma in situ
specimens, 1 solid papillary carcinoma, 1 medullary carcinoma, 1 signet ring cell carcinoma,
3 infiltrating lobular carcinomas, 22 lymph node metastases from IDC (n=20), atypical
medullary carcinoma (n=1), and infiltrating lobular carcinoma (n=1), and 11 normal breast
tissue samples. Five archival primary breast tumors were matched paired with lymph node
metastases. Handling of tissue specimens and protection of patient privacy followed strict
policies of the institutional review board of the University of North Carolina School of
Medicine.
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Formalin-fixed, paraffin-embedded human breast tissues and lymph nodes were sectioned (5
μm thick) and mounted on glass microscope slides. Immunohistochemical staining was
performed according to standard methods. Briefly, tissue sections were incubated on a slide
warmer at 60°C for 15 minutes, deparaffinized in xylene, incubated with 3% H2O2 in methanol
to block endogenous peroxidase activity, and rehydrated through a series of ethanol washes.
Antigen retrieval was accomplished by steaming in 1X citrate buffer (Dako Inc., Carpinteria,
CA) for 30 minutes. After incubation with serum-free protein block (Dako Inc.) for 10 minutes,
tissues were incubated for 2 hours at room temperature with polyclonal rabbit anti-cystatin M
antibodies diluted 1:1000 (Zhang et al., 2004). Subsequently, tissues were washed and layered
with a two-step secondary set-up including a anti-rabbit biotintylated link and streptavidin-
conjugated HRP solution (Dako Inc.) for 10 minutes each, incubated with HRP substrate
containing 3,3′ diaminobenzidine (Dako Inc.) for a total of 5 minutes, followed by
counterstaining with hematoxylin. Control immunostaining reactions were performed at room
temperature with mouse monoclonal anti-cytokeratin 18 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA) antibodies diluted 1:1000. Negative control staining followed the same procedure
except sections were incubated with either rabbit preimmune serum or 1x wash buffer instead
of anti-cystatin M antibody. Normal breast tissue was used as a positive control for the anti-
cystatin M antibody.
Isolation of Genomic DNA from Human Primary Breast Tumors, Lymph Nodes, and Normal
Breast Tissue
Paraffin-embedded tissue specimens were scraped or microdissected from slides using a clean
razor blade, deparaffinized, and genomic DNA was isolated using a QIAamp DNA Micro kit
(Qiagen, Inc., Valencia, VA) according to manufacturer’s instructions. Briefly, tissue samples
were incubated overnight at 56°C with proteinase K. Subsequently, carrier RNA (1 μg/μl) was
added and DNA samples were applied to columns, washed, and eluted with 35 μl of distilled
water.
Sodium Bisulfite Modification of Genomic DNA, Cloning, and Sequencing
Genomic DNA was modified with sodium bisulfite using the EZ DNA Methylation-Gold Kit
(ZYMO Research Co., Orange, CA) according to the manufacturer’s protocol. Briefly,
approximately 1.5 μg denatured genomic DNA was treated with conversion reagent, incubated
at 98°C for 10 minutes, and 53°C for 30 minutes, followed by a step-cycle program consisting
of 8 cycles of 53°C for 6 minutes and 37°C for 30 minutes. Subsequently, samples were applied
to columns, washed, desulfonated, washed and then eluted with 20 μl of elution buffer. In
general, 2 μl of modified DNA was used in subsequent PCR reactions. Sodium bisulfite-
converted DNA was amplified using primers that targeted a region of the proximal promoter
and exon 1 of CST6 encompassing nucleotides −118 to +242, which contains 46 CpG
dinucleotides (5′-GGTTTTTTGGGTTTTTTGAATTT-3′ and 5′-
CTACCCATATTATAACTAACC-3′). PCR amplification was accomplished using a step-
cycle program consisting of 40 cycles of 94°C for denaturing (1 minute), 52°C for annealing
(1.5 minute), and 72°C for extension (2 minutes). PCR products were fractionated on 2%
agarose gels containing 40 mM Tris-acetate/1.0 mM EDTA (pH 8.0) and visualized by
ethidium bromide staining. A portion of each PCR product (1 to 5 μl) was cloned into pGEM-
T Easy Vector (Promega, Madison, WI) using standard methods. Five to 12 colonies
corresponding to each tissue sample were selected and expanded in liquid culture. Plasmid
DNA was purified using the Wizard Plus SV Miniprep DNA purification kit (Promega), prior
to digestion with NcoI and NdeI (New England Biolabs, Beverly, MA) to confirm the presence
and size of the cloned insert. Validated clones were sequenced using the universal M13R3
primer with an Applied Biosystems automated sequencer at the UNC Genome Analysis Facility
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(Chapel Hill, NC). The bisulfite conversion efficiency was calculated for each sequenced clone
based upon the ratio of converted Cs (non-CpG) to total number of Cs (non-CpG) in a given
gene segment. Only clones determined to have a conversion efficiency of >95% were included
in the present study. The results of methylation analyses were expressed as total methylation
index (TMI). This measure of methylation can be applied to single CpG dinucleotides, select
groups of CpG dinucleotides, or to continuous groups of CpG dinucleotides in a given gene
segment. TMI was calculated for each tumor and clone by dividing the number of methylated
CpGs observed by the total CpGs analyzed and expressed as percent methylation (Rivenbark
et al., 2006a). For instance, in an analysis containing 46 CpG dinucleotides and 12 clones
sequenced, TMI would be calculated based upon 552 possible CpG methylation events (12 x
46). Tumors with a CST6 promoter TMI >11% were considered hypermethylated.
Statistical Analysis
Values included in the text, tables, and figures represent averages ± S.E.M. that were calculated
using the statistical function of KaleidaGraph Version 3.5 (Synergy Software, Essex Junction,
VT). An unpaired t-test was used to examine the association between CST6 methylation status
and protein expression levels among subsets of primary breast tumors, lymph node metastases,
and normal breast.
Results
Immunohistochemical Analysis of Cystatin M in Primary Breast Tumors and Lymph Node
Metastases
The expression of cystatin M was examined at the protein level using paraffin-embedded
tissues and immunohistochemical (IHC) staining. Table 1 shows primary breast tumor
designations along with tumor type, pTNM, pathological stage, and cystatin M protein
expression status. A breast tissue microarray (TMA) containing 60 tissue cores was
immunostained for cystatin M and cytokeratin 18 (CK18). Seventeen tissue cores from the
TMA could not be scored due to an absence of CK18 immunostaining. The remaining 43/60
(72%) cores (including 31 primary tumors) showed strong staining for CK18. Therefore, these
43 tissue samples from the TMA were analyzed for cystatin M expression. Immunodetection
of cystatin M in select normal human breast tissues (total n=5) and primary breast tumors (total
n=45) are shown in Fig. 1 and summarized in Table 1. Epithelial and myoepithelial cells of
5/5 (100%) normal breast tissues showed strong immunostaining for cystatin M (Fig. 1A, NB1).
Likewise, 20/45 (44%) primary tumors (Fig. 1, P3, P4, P22, and P30) were positive for cystatin
M expression. In contrast, 25/45 (56%) primary breast tumors were found to be negative for
cystatin M (Fig. 1, P1, P35 and P44), including 21/38 (55%) IDC, 1/2 (50%) ductal carcinoma
in situ (DCIS), 1/1 (100%) solid papillary carcinoma, 1/3 (33%) infiltrating lobular carcinoma,
and 1/1 (100%) signet ring cell carcinoma.
To examine cystatin M protein expression in metastatic lesions, 20 lymph nodes were obtained
for immunostaining (12 of the lymph nodes were derived from 5 primary breast tumors). Table
2 contains information related to the lymph nodes analyzed, including tumor designations,
along with tumor type, pTNM, pathological stage from matched primary tumors, and cystatin
M protein expression status. Fig. 2 shows representative cystatin M IHC staining in these
metastatic lesions. The majority (17/20, 85%) of metastatic lesions in lymph nodes were
negative for cystatin M expression (Fig. 2, P2N1, P4N1, LNM2, LNM5, LNM8, and LNM11).
In contrast, 3/20 (15%) metastatic lesions were positive for cystatin M expression (Fig. 2,
P1N1). Overall, these numbers reflect the presence of cystatin M-negative lymph node
metastases in 13/16 (81%) patients. These observations are consistent with the suggestion that
loss of cystatin M expression is a common feature of metastatic breast tumors. However, the
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presence of cystatin M-positive breast tumor in some lymph node specimens suggests that loss
of cystatin M expression is not absolutely required for tumor invasion and metastasis.
To examine the possibility that loss of cystatin M reflects a tumor progression-related event,
5 primary breast tumors and matched lymph node metastases were immunostained. Fig. 3
shows representative examples of these primary tumor/lymph node pairs. 1/5 (20%) matched
pairs were negative for cystatin M expression in both the primary breast tumor and lymph node
metastasis, indicating an early loss of cystatin M protein during breast tumorigenesis, with
persistence in the metastatic lesion (Fig. 3, P5 and P5N1). Additionally, 1/5 (20%) matched
pairs showed positive cystatin M staining in both the primary breast and lymph node tissues,
suggesting that tumor metastasis in this patient was mediated through a cystatin M-independent
pathway (Fig. 3, P3 and P3N1). The remaining 3 patients had cystatin M-positive primary
tumors, but 2/3 (67%) of the matched lymph node metastases lacked cystatin M expression
(Fig. 3, P4 and P4N1). This observation is consistent with a progression related loss of cystatin
M expression during the evolution of the metastatic clone. The remaining primary tumor/lymph
node pair lacks cystatin M expression in the primary tumor, while the lymph node metastasis
exhibits stronger staining for the cystatin M protein (Fig. 3, P1 and P1N1). This result is unclear,
but may reflect heterogeneity of cystatin M expression in this tumor. Thus, a cystatin M-
positive tumor cell population may have given rise to this metastatic lesion through a cystatin
M-independent pathway.
Methylation-Dependent Silencing of CST6 in Primary Breast Tumors and Lymph Node
Metastases
To explore the possibility that loss of cystatin M expression is related to epigenetic silencing
of CST6, we analyzed primary breast tumors and lymph node metastases for CST6 promoter
methylation. A segment of the proximal promoter and exon 1 (−118 to +242, Fig. 4A)
containing 46 CpG dinucleotides was analyzed in normal breast tissue, 11 primary breast
tumors (5 express cystatin M and 6 lack cystatin M), and 12 lymph node metastases (2 express
cystatin M and 10 lack cystatin M). Multiple clones (n=5–12) corresponding to the CST6
promoter and exon 1 from each primary tumor or lymph node metastasis were analyzed by
sodium bisulfite sequencing and individual CpGs were scored for methylation status.
Representative examples are shown in Fig. 4B. In normal breast tissue, 33/46 (72%) CpGs
were consistently unmethylated, 13/46 (28%) CpGs were methylated at an intermediate level,
and 0/46 (0%) were 100% methylated, producing a TMI of 2% (Fig. 4B, NB1). The majority
(3/5, 60%) of primary tumors that stain positive for cystatin M lack appreciable levels of
methylation, with TMI values of 0 to 5% (Fig. 4B, P4 and P3). Primary breast tumors P2 and
P9, exhibit methylation and express cystatin M. In P2, 23/46 (50%) CpGs were unmethylated,
22/46 (48%) CpGs were methylated at an intermediate level, and 1/46 (2%) was 100%
methylated, producing a TMI of 38%. In P9, the majority (33/46, 72%) of CpGs were
unmethylated, although 13/46 (28%) were 100% methylated resulting in a TMI of 28%. The
continued expression of cystatin M in P2 and P9, despite CST6 promoter hypermethylation,
suggests that there may be mechanisms to transcriptionally bypass promoter methylation. Most,
(5/6, 83%) primary breast tumors that are negative for cystatin M expression exhibit very low
levels of CST6 methylation (TMI = 0 to 3%). This finding suggests that there may be other
epigenetic or mutational mechanisms responsible for the silencing of cystatin M in these
primary breast tumors. In contrast, one tumor (P1) was negative for cystatin M protein
expression and 45/46 (98%) CpGs were methylated at an intermediate level, resulting in a TMI
of 28%. Overall, a subset of primary tumors (3/11, 27%) exhibits CST6 promoter
hypermethylation, and in one case this methylation was associated with loss of cystatin M
expression.
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The majority (7/10, 70%) of metastatic lesions that are negative for cystatin M expression
exhibit hypermethylation of the CST6 promoter/exon 1 region, with TMI values ranging from
11% to 46% (average TMI 17 ± 4%). The TMIs for cystatin M-negative lymph node metastases
were found to be statistically increased relative to that determined for normal breast
(P<0.0001). Fig. 4B shows representative methylation analyses. LNM1 and LNM5 were
methylated at 17/46 (37%) and 38/46 (83%) CpGs, respectively, resulting in TMIs of 37% and
46% (Fig. 4B, LNM1 and LNM5). P4N1 and LNM2 were 100% or intermediately methylated
at 35/46 (76%) and 38/46 (83%) CpGs respectively, with the remaining CpGs unmethylated,
reflecting TMIs of 22% and 24%. Cystatin M negative nodes P2N1, LNM3, and LNM4 were
intermediately methylated at 12/46 (26%), 34/46 (74%), and 18/46 (39%) CpGs, resulting in
TMI values of 11%, 13%, and 13% respectively. There were 3 cystatin M-negative lymph
nodes that displayed TMI values ranging from 1% to 3%. Two lymph node metastases were
positive for cystatin M and exhibit low levels of methylation. In lymph node P1N1, 23/46
(50%) CpGs were methylated at an intermediate level and 23/46 (50%) CpGs were
unmethylated. In lymph node P3N1, 8/46 (17%) CpGs were methylated at an intermediate
level, and 38/46 (83%) CpGs were unmethylated. In total, 8/12 (67%) metastatic lesions from
5/7 (71%) patients displayed CST6 promoter hypermethylation.
CST6 Gene Methylation Correlates with Loss of Cystatin M Expression in a Subset of Primary
Breast Tumors and Lymph Node Metastases
Cystatin M expression is associated with methylation status in the majority (12/23, 52%) of
tumor tissues (Fig. 5). In most cases (4/7, 57%) cystatin M-positive tumors show a lack of
CST6 promoter methylation (Fig. 5, P3, P3N1, and P4). In contrast, 3/7 (43%) cystatin M-
positive tumors exhibit CST6 hypermethylation. This result suggests the existence of other
epigenetic or genetic mechanisms that can bypass promoter hypermethylation. 8/16 (50%)
cystatin M-negative tumors exhibit CST6 promoter hypermethylation with TMI values ranging
from 11% to 46% (Fig. 5, P4N1, LNM1, and LNM5). These include one primary breast tumor
and 7 lymph node metastases that lack expression of cystatin M. The remaining 8/16 (50%)
cystatin M-negative tumors show very low levels of CST6 promoter methylation (TMI values
ranging from 0% to 3%), including 5 primary tumors and 3 metastatic lesions. Overall, the
extent of CST6 methylation corresponds with the expression of cystatin M expression in the
majority (52%) of breast neoplasms, suggesting that methylation-dependent silencing of
CST6 may represent an important mechanism for loss of cystatin M in a subset of breast
neoplasms.
Discussion
Cystatin M was originally described as exhibiting diminished expression in metastatic breast
cancer, suggesting a role in suppression of the invasive/metastatic phenotype (Sotiropoulou et
al., 1997). When exogenously expressed in human MDA-MB-435S breast cancer cells,
CST6 significantly alters the neoplastic phenotype in vitro, resulting in diminished cell
proliferation, loss of cell migration, inhibition of Matrigel invasion, and reduced endothelial
cell adhesion (Shridhar et al., 2004). Furthermore, expression of CST6 in MDA-MB-435S
breast cancer cells delays tumorigenesis by transplanted cells and suppresses spontaneous
formation of liver and lung metastases (Zhang et al., 2004). More recently, it has been shown
that CST6 is epigenetically regulated by DNA methylation-dependent silencing in breast cancer
cell lines (Ai et al., 2006; Rivenbark et al., 2006a; Schagdarsurengin et al., 2006; Shridhar et
al., 2004) and primary invasive ductal carcinomas (Ai et al., 2006; Schagdarsurengin et al.,
2006). Ai et al. showed that 12/20 (60%) primary breast tumors exhibit CST6 promoter
hypermethylation, and microdissection of individual cells from select tumors revealed that
methylation occurs in both DCIS and IDC cells (Ai et al., 2006). In a similar study,
Schagdarsurengin et al. showed that 24/40 (60%) breast carcinomas exhibited CST6 promoter
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hypermethylation, and that estrogen-receptor positive tumors were more frequently methylated
than estrogen-receptor negative tumors (Schagdarsurengin et al., 2006). While CST6 is
suggested to be epigenetically regulated through DNA methylation-dependent mechanisms in
breast cancer cell lines and primary breast tumors that lack cystatin M protein expression, tumor
metastases have not been examined for cystatin M expression or methylation status. Given a
putative role for CST6 in suppression of tumor invasion and metastasis, loss of cystatin M
expression may be one mechanism that enables tumor cells to spread from the primary site and
invade adjacent tissues (or distant sites) during breast cancer progression. Furthermore,
evidence from breast cancer cell lines suggests that CST6 promoter hypermethylation leading
to gene silencing may represent one major mechanism for loss of cystatin M in breast cancer.
CST6 is located in the chromosomal region 11q13, which is subject to amplification or loss of
heterozygosity in several cancers (Cromer et al., 2004; Keppler, 2006; Srivatsan et al., 2002).
Previously, we reported that the majority of CST6-negative breast cancer cell lines were
originally established from metastatic lesions (pleural effusions) rather than primary breast
tumors and that CST6-positive breast cancer cell line (BT-20) was derived from a primary
breast carcinoma (Rivenbark et al., 2006a). These observations argue that the loss of CST6
expression is strongly associated with the invasive/metastatic phenotype of the breast cancer
cell line and that CST6 promoter hypermethylation may be frequently involved in gene
silencing/loss. In the current study, we present evidence that metastatic breast cancers exhibit
lower levels of cystatin M protein expression and increased CST6 promoter hypermethylation
compared to primary breast tumors.
The differential CpG island methylation of CST6 between primary breast tumors and lymph
node metastases indicates that certain individual methylation events occur during or following
stromal invasion and tumor spread. We envision that there is a succession of methylation events
that lead to CST6 gene silencing in metastatic breast cancer: (i) individual CpG dinucleotides
within the promoter region are preferentially methylated resulting in decreased expression of
cystatin M in DCIS and/or primary breast carcinomas, (ii) methylation spreads throughout the
CpG island during surrounding stromal invasion of tumor cells and metastasis to the regional
lymph nodes resulting in a complete loss of cystatin M protein expression, and (iii) chromatin
remodeling occurs resulting in the stable silencing of CST6. However, breast tumors that
exhibit silencing of cystatin M but lack DNA methylation could achieve this silencing through
histone deacetylation or through a putative transcription repressor binding to the promoter
regulatory regions of CST6. Likewise, we have observed areas of tumor sections that show
strong staining for cystatin M and areas that show weak staining. This finding may indicate
that cystatin M silencing can be heterogeneous within a single breast tumor and can reflect
different levels of DNA methylation.
In summary, 56% primary breast tumors and 85% lymph node metastases expressed
significantly lower levels of cystatin M protein compared to normal breast tissue. CST6
promoter hypermethylation was seen in 48% of neoplastic lesions, and the extent of CST6
methylation correlates with loss of protein expression. In addition, lymph node metastases
exhibited diminished levels of cystatin M when compared to matched primary breast tumors.
These results suggest that methylation-dependent epigenetic silencing of CST6 represents an
important mechanism for loss of CST6 during breast tumorigenesis and loss of CST6 expression
is associated with the invasive/metastatic potential of breast cancer cells.
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Immunohistochemical analysis of cystatin M expression in human primary breast tumors. (A)
Panels show H&E and cystatin M immunostaining in the same tumors. Normal breast (NB1)
and primary tumors P3 and P4 show positive staining for cystatin M. Tumor P1 shows reduced
cystatin M staining compared to NB1. (B) Panels show cytokeratin 18 (CK18) and cystatin M
immunostaining in the same tumors. All tumors show strong staining for CK18. Tumors P22
and P30 exhibit positive cystatin M immunostaining. Tumors P35 and P44 show reduced
cystatin M staining. (Original objective lens magnification 10x).
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Immunohistochemical analysis of cystatin M expression in lymph node metastases. (A) Panels
show H&E and cystatin M immunostaining in the same lymph nodes. Lymph node P1N1 shows
positive staining for cystatin M. Lymph nodes P2N1, P4N1, LNM2, and LNM5 show reduced
cystatin M immunostaining. (B) Panels show cytokeratin 18 (CK18) and cystatin M
immunostaining in the same lymph nodes. All metastatic lesions show strong staining for CK18
and exhibit reduced cystatin M immunostaining. (Original objective lens magnification 10x).
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Immunohistochemical analysis of cystatin M expression in matched primary breast tumors and
lymph node metastases. Representative examples of matched pairs of primary breast tumors
(top panel) and lymph node metastasis (bottom panel) are shown. Primary breast tumor P1
shows reduced cystatin M immunostaining compared to its matched lymph node P1N1.
Primary breast tumor P3 and lymph node metastasis P3N1 both show positive staining for
cystatin M. Primary breast tumor P4 shows positive staining for cystatin M compared to its
matched lymph node metastasis P4N1. Primary breast tumor P5 and lymph node metastasis
P5N1 both show negative staining for cystatin M. (Original objective lens magnification 10x).
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Methylation analysis of the CST6 proximal promoter and exon 1 in representative primary
breast tumors and lymph node metastases. (A) The distribution of CpG dinucleotides proximal
to the transcription start site in the promoter (0 to −1400 nucleotides) and exon 1 (0 to +294
nucleotides) of CST6 are depicted schematically (vertical lines indicate the relative position of
individual CpG dinucleotides). Methylation analysis was performed on a region of the
promoter spanning from −118 to +242 (indicated by a solid horizontal line), which contains
46 CpG dinucleotides and encompasses a large CpG island. (B) All clones analyzed for
methylation of the CST6 promoter and exon 1 (46 CpGs) are shown for representative primary
breast tumor and lymph node metastases examples. Black circles correspond to methylated
CpGs and open circles correspond to unmethylated CpGs. TMI values for the entire promoter/
exon 1 region (46 CpGs) are given for each primary breast tumor and lymph node metastases.
NB1, P4, and P3 express cystatin M, while LNM1 and LNM5 lack cystatin M protein
expression.
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Correlation analysis of cystatin M expression and CST6 methylation status in primary breast
tumors and lymph node metastases. Panels show cystatin M immunostaining (on left) and a
summary of the methylation analysis of the CST6 promoter/exon 1 (46 CpGs) is show on the
right. Black circles correspond to fully (100%) methylated CpGs, gray circles correspond to
CpGs with intermediate methylation, and open circles correspond to unmethylated CpGs. TMI
values for the entire promoter/exon 1 region (46 CpGs) are given for each tissue sample. P4
and P3 primary breast tumors, and lymph node metastasis P3N1 express cystatin M. Metastatic
lesions P4N1, LNM1, and LNM5 show reduced expression of cystatin M. (Original objective
lens magnification 10x).
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Table 1
Characteristics of human primary breast tumors and normal breast tissues.
Tissue Designation1 Tumor Type2 pTNM Stage Cystatin M Expression
P1 IDC T2N1Mx IIB No
P2 IDC T1cN3aMx IIIC Yes
P3 IDC T2N1Mx IIB Yes
P4 IDC T2N1Mx IIB Yes
P5 IDC T1cN2aMx IIIA No
P6 IDC T1NxMx UNK No
P7 IDC TxNxMx3 IIA Yes
P8 IDC T2N1Mx IIB No
P9 IDC T1bN0Mx I No
P10 IDC T1cN1Mx IIA No
P11 IDC T1N1Mx IIA No
P12 IDC T2N1Mx IIB No
P13 IDC T4N3M1 IV Yes
P14 IDC T1N0Mx I Yes
P15 solid papillary carcinoma T3N1aM0 IIIA No
P16 IDC T4bN2aM0 IIIB No
P17 IDC T3N0M0 IIB No
P18 IDC T3N1aM0 IIIA No
P19 IDC T3N3aN0 IIIC No
P20 infiltrating lobular carcinoma T2N1aM0 IIB Yes
P21 IDC T3N1aM0 IIIA Yes
P22 IDC T2N1aM0 IIB Yes
P23 infiltrating lobular carcinoma T3N3aM0 IIIC Yes
P24 infiltrating lobular carcinoma T3N3aM0 IIIC No
P25 IDC T2N1aM0 IIB No
P26 IDC T2N0M0 IIA No
P27 DCIS TisN0M0 0 No
P28 IDC T2N2aM0 IIIA Yes
P29 IDC T2N3bM0 IIIC Yes
P30 DCIS TisN0M0 0 Yes
P31 IDC T2N2M0 IIIA Yes
P32 IDC T2N0M0 IIA No
P33 IDC T2N0M0 IIA Yes
P34 signet ring cell carcinoma T3N0M0 IIB No
P35 IDC T3N2aM0 IIIA No
P36 IDC T3N2aM0 IIIA No
P37 IDC T2N0M0 IIA Yes
P38 IDC T2N0M0 IIA Yes
P39 IDC T2N2aM0 IIIA Yes
P40 IDC T2N0M0 IIB Yes
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Tissue Designation1 Tumor Type2 pTNM Stage Cystatin M Expression
P41 IDC T3N1aM0 IIIA No
P42 IDC T2N1aM0 IIB Yes
P43 IDC T2N0M0 IIA No
P44 IDC T3N2aM0 IIIA No
P45 IDC T3N1aM0 IIIA No
NB1 Normal NA NA Yes
NB2 Normal NA NA Yes
NB3 Normal NA NA Yes
NB4 Normal NA NA Yes
NB5 Normal NA NA Yes
1
Primary breast tumors are indicated as Px and normal breast tissues are designated NBx.
2
IDC refers to invasive ductal carcinoma and DCIS refers in ductal carcinoma in situ.
3
TxNxMx refers to a pTNM that is unknown.
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Table 2
Characteristics of human lymph node metastases.
Tissue Designation1 Tumor Type pTNM2 Stage2 Cystatin M Expression
P1N1 lymph node metastasis T2N1Mx IIB Yes
P2N1-N33 lymph node metastasis T1cN3aMx IIIC No
P3N1 lymph node metastasis T2N1Mx IIB Yes
P4N1 lymph node metastasis T2N1Mx IIB No
P5N1 lymph node metastasis T1cN2aMx IIA No
LNM1-44 lymph node metastasis TxNxMx UNK No
LNM5 lymph node metastasis TxNxMx UNK No
LNM6 lymph node metastasis T3N3aM0 IIIC Yes
LNM7 lymph node metastasis T3N3aM0 IIIC No
LNM8 lymph node metastasis T3N3aM0 IIIC No
LNM9 lymph node metastasis T3N3M0 IIIC No
LNM10 lymph node metastasis T3N2aM0 IIIA No
LNM11 lymph node metastasis T1cN1aM0 IIA No
LMN12 lymph node metastasis T2N3aM0 IIIC No
LMN13 lymph node metastasis T1bN3aM0 IIIC No
1
Metastaic lesions corresponding to a matched primary breast tumor are indicated as PxNx and lesions that have no matched primary are designated
LNMx.
2
pTNM and pathological stage designations for lymph node metastases are derived from primary breast tumor designations. TxMxNx refers to a pTNM
that is unknown.
3
P2N1-N3 designates 3 independent lymph nodes corresponding to one primary tumor.
4
LNM1-4 designates 4 independent lymph nodes corresponding to one primary tumor.
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